A new Ebola drug grown from special tobacco plants has been shown to cure monkeys that were already displaying signs of infection by the viral hemorrhagic fever, the Los Angeles Times reported on Wednesday.
Other Ebola countermeasures have been shown to work on infected animals before they start displaying symptoms of the highly virulent and lethal disease. However, this is the first time a drug has demonstrated any effectiveness after signs of the virus have manifested. That is regarded as a crucial capability in the event of a real-life disease epidemic, according to virologist Gene Olinger, who works at the Army Medical Research Institute of Infectious Diseases at Fort Detrick, Md.
“We’ve pushed the opportunity to treat people to the point where they walk in and say, ‘I have a fever,’” said Olinger, co-author of a report on the new Ebola drug published by the Science Translational Medicine journal on Wednesday. “A lot of folks in the field would have thought protecting an animal at the time of fever and viremia is too late to have a clinical benefit.”
Ebola is one of the most deadly and contagious diseases known to exist in nature. The lack of adequate vaccines and antidotes for the disease have made it a serious worry for biodefense specialists concerned about its possible applications as a biological weapon.
In the recent study, seven infected rhesus monkeys were administered the experimental treatment MB-003 through their veins once every three days. Three of the monkeys did not die, resulting in a statistically notable success rate of 43 percent.
Fort Detrick scientist and lead study author James Pettitt said it is probable that in a real-life outbreak, the drug would be administered at a higher dosage and with greater frequency.
“We think we’ll get better results,” the researcher said.
Growing the drug from specially developed tobacco leaves is not only less costly than conventional cell-based methods, but also allows for large batches of the drug to be produced on fairly short, weeklong schedules, according to the Times article.
Olinger said further measures will be taken to improve MB-003 by adding to it more Ebola antibodies that were discovered by a different group of researchers.
What We're Following See More »
The National Defense Authorization Act passed the House this morning by a 375-34 vote. The bill, which heads to the Senate next week for final consideration, would fund the military to the tune of $618.7 billion, "about $3.2 billion more than the president requested for fiscal 2017. ... The White House has issued a veto threat on both the House and Senate-passed versions of the bill, but has not yet said if it will sign the compromise bill released by the conference committee this week."
"Republicans have elected Rep. Greg Walden (R-OR) the next chairman of the powerful House Energy and Commerce Committee. Walden defeated Reps. John Shimkus (R-IL) and Joe Barton (R-TX), the former committee chairman, in the race for the gavel" to succeed Michgan's Fred Upton.
"Democratic and Republican members of the Senate Judiciary Committee are working on legislation that would limit deportations" under President-elect Donald Trump. Leading the effort are Judiciary Committee members Dick Durbin (D-IL) and Lindsey Graham (R-SC). Sen. Jeff Flake (R-AZ) is also expected to sign on.
Donald Trump has selected retired Marine Gen. James 'Mad Dog' Mattis as his secretary of defense, according to The Washington Post. Mattis retired from active duty just four years ago, so Congress will have "to pass new legislation to bypass a federal law that states secretaries of defense must not have been on active duty in the previous seven years." The official announcement is likely to come next week.